Get startedLog in
    Picture of Avidity Biosciences logo

    RNA — Avidity Biosciences News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapNeutral
    All News

    Brief: Avidity Biosciences Announces Completion Of Enrollment For HARBOR™, The First Global Phase 3 Trial Of Delpacibart Etedesiran (Del-Desiran) For Treatment Of DM1 And Provides Guidance On Regulatory Submission

    Picture of Avidity Biosciences logoAvidity Biosciences
    28/07/2025 14:18
    July 28 (Reuters) - Avidity Biosciences Inc RNA.O:

AVIDITY BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT FOR HARBOR™, THE FIRST GLOBAL PHASE 3 TRIAL OF DELPACIBART ETEDESIRAN (DEL-DESIRAN) FOR TREATMENT OF DM1 AND PROVIDES GUIDANCE ON REGULATORY SUBMISSION

Source text: ID:nPn72g55Ba

Further company coverage: RNA.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Avidity Biosciences

    See all news